A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.

Hyun YangHyun Young WooSoon Kyu LeeJi Won HanBohyun JangHee Chul NamHae Lim LeeSung Won LeeDo Seon SongMyeong Jun SongJung Suk OhHo Jong ChunJeong Won JangAngelo LozadaSi Hyun BaeJong Young ChoiSeung Kew Yoon

Published in: Clinical and molecular hepatology (2017)

MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.

Keyphrases

primary care
tyrosine kinase
squamous cell carcinoma
type diabetes
metabolic syndrome
adipose tissue
locally advanced
rectal cancer